Therapeutic Asset Ratings

3,589 results matching 1 filter

134,009 assets · 8,804 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Autologous Cd33/Cd123 Dual-Target Car-T Module Plasma Cell Myeloma	Beijing Biotech	P1/2	CC (47)
Autologous Cd33/Cll1 Dual-Target Car-T Module B-Cell Acute Lymphoblastic Leukemia	Beijing Biotech	P1/2	CC (47)
Autologous Cd33/Cll1 Dual-Target Car-T Module B-Cell Non-Hodgkin Lymphoma	Beijing Biotech	P1/2	CC (47)
Autologous Cd33/Cll1 Dual-Target Car-T Module Plasma Cell Myeloma	Beijing Biotech	P1/2	CC (47)
Autologous Cd5/Cd7 Dual-Target Car-T Module B-Cell Acute Lymphoblastic Leukemia	Beijing Biotech	P1/2	CC (47)
Autologous Cd5/Cd7 Dual-Target Car-T Module B-Cell Non-Hodgkin Lymphoma	Beijing Biotech	P1/2	CC (47)
Autologous Cd5/Cd7 Dual-Target Car-T Module Plasma Cell Myeloma	Beijing Biotech	P1/2	CC (47)
Autologous Cd7 Car T-Cell T-Cell And NK-Cell Neoplasm	Beijing GoBroad Hospital	P1/2	CC (47)
Autologous Dual-Target Car-T Cells Selected From The Predefined Target Library. Metastatic Neoplasm	Beijing Biotech	P1/2	CC (47)
Autologous Hucd19 Car T Cells Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	National Cancer Institute (NCI)	P1/2	CC (47)
Autologous Immune Cells Breast Cancer	Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.	P1/2	CC (47)
Autologous Immune Cells Colorectal Cancer	Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.	P1/2	CC (47)
Autologous Immune Cells Liver Cancer	Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.	P1/2	CC (47)
Autologous Nk Cell B-Cell Non-Hodgkin Lymphoma	Xiangyang No.1 People's Hospital	P1/2	CC (47)
Autologous Nk Cell NK Cell	Xiangyang No.1 People's Hospital	P1/2	CC (47)
Autologous T cells obtained from peripheral blood mononuclear cells by leukapheresis, transduced with a self-inactivating, nonreplicating lentiviral vector, encoding a T cell chimeric antigen receptor targeting CD19. The expressed transgene comprises a CD8? leader sequence, a murine anti-CD19 single chain variable fragment (scFv) derived from the mouse hybridoma FMC63, a CD8? hinge and transmembrane region, and a 4-1BB (CD137) and CD3? (TCR?) signaling domain and is under control of the elongation factor 1 alpha (EF1?) promoter. The construct is flanked by 5' and 3' long terminal repeats (LTRs) and also contains a ? packaging signal, a Rev response element (RRE), a central polypurine tract (cPPT) sequence and an optimized Woodchuck hepatitis virus posttranscriptional regulatory element (WPRE). The leukapheresis material is enriched for CD4/CD8 T cells by positive immunoselection, activated by CD3 and CD28 agonists and transduced with the vector. Without further cell propagation, the T cells are washed, formulated for infusion, and cryopreserved. The substance is composed of ?80% T cells and ?1% B cells, with a mixture of transgene positive (>3.4%) and negative T cells. The CD4+ and CD8+ naïve T cell subsets (CD45RA+CCR7+) present in the leukapheresis material are largely retained Chronic Progressive Multiple Sclerosis	Novartis Pharmaceuticals	P1/2	CC (47)
Baff-R Car-T Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	P1/2	CC (47)
Baff-R Car-T Diffuse Large B-Cell Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	P1/2	CC (47)
Baff-R Car-T Mantle Cell Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	P1/2	CC (47)
Bcma/Gprc5D Car-T Cells Sarcoma of Bone and Connective Tissue	Essen Biotech	P1/2	CC (47)
Bpx-501 T Cells Aplastic Anemia	Bellicum Pharmaceuticals	P1/2	CC (47)
Bpx-501 T Cells Cytopenia	Bellicum Pharmaceuticals	P1/2	CC (47)
Bpx-501 T Cells Childhood Acute Myeloid Leukemia	Bellicum Pharmaceuticals	P1/2	CC (47)
Bpx-501 T Cells Osteopetrosis	Bellicum Pharmaceuticals	P1/2	CC (47)
Bpx-501 T Cells Inborn Error Of Immunity	Bellicum Pharmaceuticals	P1/2	CC (47)

Showing 776 to 800 of 3,589 assets

PreviousPage 32 of 144Next